logo
Norse Atlantic can get you to Europe for cheap. Here's what it's like.

Norse Atlantic can get you to Europe for cheap. Here's what it's like.

Washington Post18-07-2025
On my hunt for flights to Europe this summer, one airline stood above — or should I say below — the rest.
Norse Atlantic Airways, a transatlantic budget airline based in Norway, kept emerging from my Google Flights searches as the most affordable way to get across the pond. Fares were dirt cheap, like a one-way ticket from New York to Berlin for $150.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Yahoo

time11 minutes ago

  • Yahoo

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Johnson & Johnson's (JNJ) Defensive Strength Shines Among the Dogs of the Dow
Johnson & Johnson's (JNJ) Defensive Strength Shines Among the Dogs of the Dow

Yahoo

time11 minutes ago

  • Yahoo

Johnson & Johnson's (JNJ) Defensive Strength Shines Among the Dogs of the Dow

Johnson & Johnson (NYSE:JNJ) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A smiling baby with an array of baby care products in the foreground. Johnson & Johnson (NYSE:JNJ) has a sizable and broadly positioned operation, with strong representation in both the medical devices and pharmaceutical sectors. Its leading status in the industry is also supported by its robust efforts in research and development, as well as effective marketing capabilities. In the second quarter of 2025, Johnson & Johnson (NYSE:JNJ) reported revenue of $23.7 billion, which showed a 5.77% growth from the same period last year. The company raised its full-year sales outlook by $2 billion to reflect a 5.4% increase, thanks to solid operational performance and positive foreign exchange impacts. It also boosted its earnings per share (EPS) forecast by $0.25, bringing it to $10.85. Meanwhile, adjusted operational EPS was revised to $10.68 at the midpoint. In its earnings report, Johnson & Johnson (NYSE:JNJ) indicated that its portfolio and pipeline have set the stage for accelerated growth in the latter half of the year. It expects significant approvals and regulatory submissions in key areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular health— advancements that are likely to enhance and extend lives in meaningful ways. Johnson & Johnson (NYSE:JNJ) is favored because of its strong dividend policy. The company has been growing its dividends for 63 consecutive years and currently pays a quarterly dividend of $1.30 per share. With a dividend yield of 3.09%, as of July 26, JNJ is among the best dogs of the Dow to invest in. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store